The Backlash Against Bioequivalence and the Interchangeability of Brand-Name and Generic Drugs

The author addresses skepticism about generic drug interchangeability, arguing that while case reports of adverse outcomes from generic substitution have fueled concerns, particularly for narrow therapeutic index drugs, the overall evidence strongly supports the bioequivalence framework, and that opposition is often driven by anecdote rather than systematic data.